Evidence map›Paper›PMID 39204321›Full record

ReviewPharmaceutics2024

Recent Progress in Multifunctional Stimuli-Responsive Combinational Drug Delivery Systems for the Treatment of Biofilm-Forming Bacterial Infections.

Davoodbasha MubarakAli, Kandasamy Saravanakumar, Archchana Ganeshalingam, Sugavaneswaran Siva Santosh, Shanali De Silva, Jung Up Park, Chang-Min Lee, Su-Hyeon Cho, Song-Rae Kim, Namki Cho and 2 more

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Davoodbasha MubarakAliSchool of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai 600048, Tamil Nadu, India.ORCID 0000-0001-8133-8676
Kandasamy SaravanakumarResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.ORCID 0000-0002-4465-4378
Archchana GaneshalingamCollege of Chemical Sciences, Institute of Chemistry Ceylon, Welikada, Rajagiriya 10107, Sri Lanka.ORCID 0000-0002-0858-4341
Sugavaneswaran Siva SantoshTechnical University of Munich, Campus Straubing, 94315 Straubing, Germany.
Shanali De SilvaCollege of Chemical Sciences, Institute of Chemistry Ceylon, Welikada, Rajagiriya 10107, Sri Lanka.
Jung Up ParkDivision of Practical Application, Honam National Institute of Biological Resources, 99, Gohadoan-gil, Mokpo-si 58762, Republic of Korea.
Chang-Min LeeDepartment of Veterinary Internal Medicine, College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, Gwangju 61186, Republic of Korea.
Su-Hyeon ChoGwangju Center, Korea Basic Science Institute (KBSI), Gwangju 61751, Republic of Korea.
Song-Rae KimMetropolitan Seoul Center, Korea Basic Science Institute (KBSI), Seoul 03759, Republic of Korea.ORCID 0000-0002-2736-5187
Namki ChoResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju 61186, Republic of Korea.
Gobika ThiripuranatharCollege of Chemical Sciences, Institute of Chemistry Ceylon, Welikada, Rajagiriya 10107, Sri Lanka.ORCID 0000-0002-0904-9519
SeonJu ParkMetropolitan Seoul Center, Korea Basic Science Institute (KBSI), Seoul 03759, Republic of Korea.ORCID 0000-0002-0532-5977

Funding

Korea Basic Science Institute K413000Korea Institute of Marine Science & Technology Promotion (KIMST), funded by the Ministry of Oceans and Fisheries G22202201282201Ministry of Education, Science, and Technology, Republic of Korea NRF-2022R1F1A1063364National Research Foundation (NRF) of Korea 2022R1I1A1A01067464
6 · The paper itself

Abstract

Drug-resistant infectious diseases pose a substantial challenge and threat to medical regimens. While adaptive laboratory evolution provides foresight for encountering such situations, it has inherent limitations. Novel drug delivery systems (DDSs) have garnered attention for overcoming these hurdles. Multi-stimuli responsive DDSs are particularly effective due to their reduced background leakage and targeted drug delivery to specific host sites for pathogen elimination. Bacterial infections create an acidic state in the microenvironment (pH: 5.0-5.5), which differs from normal physiological conditions (pH: 7.4). Infected areas are characterized by the overexpression of hyaluronidase, gelatinase, phospholipase, and other virulence factors. Consequently, several effective stimuli-responsive DDSs have been developed to target bacterial pathogens. Additionally, biofilms, structured communities of bacteria encased in a self-produced polymeric matrix, pose a significant challenge by conferring resistance to conventional antimicrobial treatments. Recent advancements in nano-drug delivery systems (nDDSs) show promise in enhancing antimicrobial efficacy by improving drug absorption and targeting within the biofilm matrix. nDDSs can deliver antimicrobials directly to the biofilm, facilitating more effective eradication of these resilient bacterial communities. Herein, this review examines challenges in DDS development, focusing on enhancing antibacterial activity and eradicating biofilms without adverse effects. Furthermore, advances in immune system modulation and photothermal therapy are discussed as future directions for the treatment of bacterial diseases.

Indexed as

bacterial infectioncombination therapydrug delivery systemsstimuli-responsive

Identifiers

PMID39204321
PMCPMC11359499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.